| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- KO-947
-
- $44.00
-
2026-07-27
- CAS:1695533-89-1
- Purity: 97.84%
- Supply Ability: 10g
|
| Product Name: | KO-947 | | Synonyms: | KO-947;6-benzyl-3-(pyridin-4-yl)-5,6-dihydro-1H-pyrazolo[4,3-g]quinazolin-7(8H)-one;KO947;KO-947;KO 947;7H-Pyrazolo[4,3-g]quinazolin-7-one, 1,5,6,8-tetrahydro-6-(phenylmethyl)-3-(4-pyridinyl)-;Inhibitor,ERK,KO-947,inhibit,KO 947,Extracellular signal regulated kinases,KO947;6-benzyl-3-(pyridin-4-yl)-1H,5H,6H,7H,8H-pyrazolo[4,3-g]quinazolin-7-one;KO-947 ，S8569 | | CAS: | 1695533-89-1 | | MF: | C21H17N5O | | MW: | 355.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1695533-89-1.mol |  |
| | KO-947 Chemical Properties |
| Boiling point | 704.1±60.0 °C(Predicted) | | density | 1.354±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | solubility | DMSO:66.75(Max Conc. mg/mL);187.82(Max Conc. mM) | | form | A crystalline solid | | pka | 13.32±0.20(Predicted) | | color | White to off-white |
| | KO-947 Usage And Synthesis |
| Description | KO947 is an ERK inhibitor (IC50 = <50 nM for ERK2). It is greater than 50-fold selective for ERK over a panel of 450 kinases. KO947 reduces phosphorylation of the ERK target p90 ribosomal S6 kinase (RSK) in A375 cancer cells containing constitutively active B-RAFV600E with an IC50 value of less than 250 nM. It inhibits proliferation of A375 cells, as well as mutant K-Ras-expressing HCT116 and H358 cancer cell lines (IC50s = 50-250 nM for all). | | Uses | KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors. | | in vivo | In cell-line derived xenograft studies, KO-947 profoundly suppresses ERK signaling for up to five days after a single dose and induces regressions in RAS- and RAF-mutant melanoma, NSCLC and pancreatic cancer models on administration schedules ranging from daily to weekly. Intermittent dosing enables comparable antitumor activity at reduced dose-intensity[1]. | | IC 50 | ERK1; ERK2 | | References | [1] Burrows F, et al. KO-947, a potent ERK inhibitor with robust preclinical single agent activity in MAPK pathway dysregulated tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5168. doi:10.1158/1538-7445.AM2017-5168. |
| | KO-947 Preparation Products And Raw materials |
|